玻璃体腔注射康柏西普治疗湿性老年黄斑变性的疗效

发布时间：2018-11-07 09:58

【摘要】：目的:观察玻璃体腔注射康柏西普治疗湿性老年性黄斑变性(age-related macular degeneration,AMD)的有效性及安全性。方法:回顾性分析。经眼科常规检查、荧光素眼底血管造影(FFA)、相干光断层扫描(OCT)检查确诊为湿性AMD的患者20例22眼,给予所有患眼玻璃体腔注射10mg/mL康柏西普0.5mg,每月注射1次,连续3次为初始治疗,后根据病情需要决定是否重复治疗。每月随访1次,随访观察≥6mo。对比分析治疗前后患眼最佳矫正视力(BCVA)、中心视网膜厚度(CRT)及黄斑区脉络膜新生血管(CNV)病灶渗漏变化情况。结果:治疗后1、3、6mo患眼平均BCVA(LogM RA)均较治疗前提高,差异具有统计学意义(P0.01)。治疗后1、3、6mo患眼平均CRT均较治疗前降低,差异具有统计学意义(P0.01)。末次随访时,FFA检查,黄斑区CNV病灶渗漏消失20眼(90%);渗漏减轻2眼(9%)。随访期间未见与治疗相关的严重眼部并发症及全身严重不良反应发生。结论:临床实际应用玻璃体腔注射康柏西普治疗湿性AMD可提高患眼视力,降低患眼CRT,抑制新生血管渗漏,无与治疗相关的不良反应发生。
[Abstract]:Objective: to observe the efficacy and safety of intravitreous injection of Compactopril in the treatment of wettable age-related macular degeneration (age-related macular degeneration,AMD). Methods: retrospective analysis. Twenty patients (22 eyes) with wet AMD diagnosed by fluorescein fundus angiography (FFA),) coherence tomography (OCT) were given intravitreous injection of 10mg/mL (0.5 mg) into the vitreous cavity of all eyes and once a month. Three consecutive times of initial treatment, and then according to the need to determine whether to repeat treatment. The patients were followed up once a month and more than 6 moths were observed. The changes of central retinal thickness (CRT) and choroidal neovascularization (CNV) in macular area before and after treatment were analyzed. Results: the average BCVA (LogM RA) of the eyes was significantly higher than that before treatment at 1: 3 and 6 mo after treatment (P0.01). The average CRT of the eyes was significantly lower than that before treatment at 1: 3 and 6 mo after treatment (P0.01). At the last follow-up, FFA showed that CNV leakage disappeared in 20 eyes (90%) and decreased in 2 eyes (9%). There were no severe ocular complications and systemic adverse reactions associated with treatment during follow-up. Conclusion: the clinical application of intravitreal injection of Compactopril in the treatment of wet AMD can improve the visual acuity of the affected eyes and reduce the inhibition of neovascularization by CRT,. There are no adverse reactions associated with the treatment.
【作者单位】：中国陕西省宝鸡市人民医院眼科;
【分类号】：R774.5

【相似文献】